The role of peritoneal dialysis as the first-line renal replacement modality

Peritoneal Dialysis International

Volumn 20, Issue 4, 2000, Pages 375-383

  Van Biesen, W ^a   Vanholder, R ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSEL FUNCTION; BURNOUT; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; EDITORIAL; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MEDICAL INFORMATION; MEDICAL RESEARCH; NONHUMAN; PERITONEAL DIALYSIS; PERITONITIS; PRIMARY HEALTH CARE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT INDICATION; ULTRAFILTRATION;

EID: 0033789453     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002000401     Document Type: Editorial

References (94)

1. Peritoneal dialysis
2. End-stage renal disease treatment: A European perspective
3. A critical examination of trends in outcomes over the last decade
4. Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates
5. ESRD modality selection into the 21st century: The importance of non-medical factors
6. Non-medical factors that impact on ESRD modality selection
7. The pattern of referral of patients with end-stage renal disease to the nephrologist: A European survey
8. Technique failure in peritoneal dialysis and its impact on patient survival
9. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years
10. A comparison of survival among dialytic therapies of choice: In-center hemodialysis versus continuous ambulatory dialysis at home
11. What is the place of peritoneal dialysis in the integrated treatment of renal failure
12. An evaluation of an integrative care approach for the treatment of ESRD patients
13. CAPD viability: A long-term comparison with hemodialysis
14. Outcome of peritoneal dialysis: Comparative studies
15. What really happens to people on long term peritoneal dialysis?
16. Analysis of the reasons for transfer between hemodialysis and peritoneal dialysis and their effects on survival
17. Vascular access: Concepts for the 1990s
18. Correlates of vascular access and nonvascular access related hospitalizations in hemodialysis patients
19. Vascular access survival among incident hemodialysis patients in the United States
20. Hemodialysis access failure: A call to action
21. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys
22. Dialysis modality and delayed graft function after cadaveric renal transplantation
23. Renal transplantation in patients undergoing chronic peritoneal dialysis
24. Peritoneal dialysis favorably influences recovery of renal function after transplantation
25. Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared to hemodialysis
26. Impact of pretransplantation dialysis modality on patient outcome after renal transplantation: The role of peritoneal dialysis revisited
27. Delayed graft function: Immediate and late impact
28. Hemodialysis vascular access morbidity
29. Technique failure in peritoneal dialysis and its impact on patient survival
30. Hepatitis C virus infection in dialysis and renal transplantation
31. The impact of renal transplantation on the course of hepatitis B liver disease
32. Incidence and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: Evidence for environmental transmission
33. Protective effects of hepatitis B vaccine in chronic hemodialysis patients
34. Nosocomial transmission of hepatitis C virus infection in a hemodialysis unit during two years of prospective follow-up
35. Incidence and risk factors for hepatitis seroconversion in hemodialysis: A prospective study
36. Molecular evidence for nosocomial transmission of hepatitis in a French hemodialysis unit
37. High incidence of hepatitis C virus infection in hemodialysis patients in Taiwan
38. Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients
39. Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous ambulatory peritoneal dialysis
40. The influence of dialysis treatment modality on the decline of remaining renal function
41. Preservation of residual renal function in maintenance dialysis patients
42. The impact of residual renal function on the adequacy of peritoneal dialysis
43. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcome
44. Morbidity and mortality in redefining adequacy of peritoneal dialysis: A step beyond the national kidney foundation dialysis outcomes quality initiative
45. A longitudinal, five year survey of urea kinetic parameters in CAPD patients
46. The impact of peritoneal permeability and residual renal function on PD prescription
47. Impact of increasing dialysis volume on adequacy targets: A prospective study
48. Loss of residual renal function in patients on regular hemodialysis
49. Residual renal function and recovery of renal function in patients treated by CAPD
50. Rapid decline of residual renal function in patients on automated peritoneal dialysis
51. The influence of automated peritoneal dialysis on the decrease in residual renal function
52. The use of polysulphone dialyzers slows the rate of intrinsic renal function loss in chronic hemodialysis patients
53. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients
54. Choice of dialysis membrane does not influence the outcome of residual renal function in hemodialysis patients
55. Peritoneal solute transport predicts survival on CAPD independently of residual renal function
56. Role of ″uremic toxin″ in the progressive loss of intact nephrons in chronic renal failure
57. Indoxyl sulphate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis
58. Efficient removal of albumin-bound furancarbolic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis
59. Timely initiation of dialysis by DOQI guidelines: Maintenance of residual renal function
60. The clinical epidemiology of cardiac disease in chronic renal failure
61. Long term evolution of cardiomyopathy in dialysis patients
62. Mode of dialysis therapy and mortality in end stage renal disease
63. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis
64. Effect of continuous ambulatory peritoneal dialysis on blood pressure control
65. Cardiovascular disease in peritoneal dialysis
66. Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?
67. Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men
68. Multicenter study of lipoprotein (a) and apolipoprotein (a) phenotypes in patients with end stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis
69. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
70. Does the choice of renal replacement therapy adversely affect hypercoagulability associated with renal disease?
71. Hypercoagulability and secondary hyperfibrinolysis may be due to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis
72. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
73. Malnutrition, cardiac disease and mortality: An integrated point of view
74. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities
75. Healthcare systems and end stage renal disease therapies: An international review: Costs and reimbursement/funding of ESRD therapies
76. Dialysis in patients with diabetic nephropathy: CAPD versus hemodialysis
77. Profile of patients on RRT in Europe and death rates due to major causes of death groups
78. Current status of renal replacement therapy in Japan
79. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease
80. Mortality in end-stage renal disease: A reassessment of differences between patients treated with hemodialysis and peritoneal dialysis
81. Continuous ambulatory peritoneal dialysis and hemodialysis: Comparison of patient mortality with adjustment for comorbid conditions
82. Renal replacement therapies in the elderly: Hemodialysis and peritoneal dialysis
83. Peritoneal dialysis versus hemodialysis in the elderly
84. Treatment costs for peritoneal and hemodialysis therapy in Germany: Results from a prospective cost-comparison analysis approach
85. Analysis and interpretation of cost data in dialysis: Review of Western European literature
86. Hospitalization among United States dialysis patients: Hemodialysis versus peritoneal dialysis
87. Hospitalization in peritoneal dialysis patients
88. Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment
89. Quality of life over time in dialysis: The Netherlands cooperative study on the adequacy of dialysis. NECOSAD study group